RBC Capital analyst Ben Hendrix lowered the firm’s price target on Acadia Healthcare (ACHC) to $28 from $43 and keeps an Outperform rating on the shares after its Q2 results. Acute care volumes came in slightly below expectations, while weaker Medicaid volume was the primary driver of the company’s revised 2025 outlook, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Acadia Healthcare price target lowered to $25 from $44 at TD Cowen
- Acadia Healthcare: Buy Rating Amid Growth Potential and Operational Challenges
- Acadia Healthcare: Strategic Adjustments and Growth Prospects Justify Buy Rating Amid Medicaid Challenges
- Acadia Healthcare price target lowered to $20 from $28 at Barclays
- Acadia Healthcare Reports Strong Q2 2025 Results